Tevogen Bio Signs LOI to Explore Acquiring HRK Healthcare LLC
Nasdaq-listed Tevogen Inc. has signed a non-binding letter of intent to evaluate a potential acquisition of HRK Healthcare LLC.
Tevogen Inc., a Warren, N.J.-based healthcare company traded on Nasdaq under the ticker TVGN, announced Wednesday it has signed a non-exclusive, non-binding letter of intent to evaluate a potential transaction with HRK Healthcare LLC, according to a company statement.
The letter of intent marks a preliminary step in what could become a formal acquisition, though no binding agreement is in place and no terms have been disclosed. Such non-binding instruments are standard early-stage tools used by companies to signal mutual interest while both parties conduct due diligence.
Read more X4 Pharmaceuticals Lands $150M Debt Facility With K2 HealthVentures →
Tevogen describes itself as an integrated healthcare enterprise that combines biopharmaceutical development, artificial intelligence, and healthcare services with a stated focus on improving the affordability and accessibility of life-saving medicines. An acquisition of HRK Healthcare, if completed, could expand its service or operational footprint, though specifics of any deal remain undefined at this stage.
The announcement comes as healthcare companies increasingly pursue consolidation strategies to achieve scale, reduce costs, and broaden patient access — trends that align with Tevogen's stated mission. Investors and analysts will likely monitor whether the exploratory process advances to a definitive agreement in the coming weeks or months.
Continue reading at GlobeNewswire - Industry News on Financial Services.
